News about Drug Discovery & Development

Lupin Gets Tentative Approval from US FDA for RLD Sutab

Lupin has secured tentative approval from US FDA for its Abbreviated New Drug Application for Sodium Sulfate, Magnesium Sulfate, and Potassium Chloride Tablets, 1.479 g/0.225 g/0.188 g, to market a generic equivalent of Sutab Tablets, 1.479 g/0.225 g/0.188 g, of Braintree Laboratories Inc.

Drug Discovery & Development | 18/07/2024 | By Aishwarya |  611

Nona Biosciences Signs Partnership Deal with Alaya.bio to Advance CAR-T Cell Therapy

Nona Biosciences has entered into a collaboration agreement with Alaya. bio to precisely target and reprogram cells in situ and thus to significantly simplify the way CAR-T cell therapies in particular are being developed, manufactured and administered.

Drug Discovery & Development | 15/07/2024 | By Aishwarya |  630

Dr. Reddy's Laboratories Launches Muslaxin in Russia

Dr. Reddy's Russia arm, part of the global pharmaceutical company Dr. Reddy’s Laboratories, has introduced Muslaxin (INN Ibuprofen 400 mg + Chlorzoxazone 500 mg), the first combination drug of NSAID and muscle relaxant that does not have generics in the Russian Federation.

Drug Discovery & Development | 12/07/2024 | By Aishwarya |  2084

Nusano and PharmaLogic to Offer Current and Emerging Radiopharmaceuticals

Nusano Inc. has inked a supply agreement with PharmaLogic to provide a more efficient and reliable supply of critical radioisotopes.

Drug Discovery & Development | 11/07/2024 | By Aishwarya |  248

Alembic Pharma Gets USFDA Approval for Bromfenac Ophthalmic Solution

Alembic Pharmaceuticals has secured final approval from the US Food and Drug Administration (USFDA) for its generic Bromfenac Ophthalmic Solution.

Drug Discovery & Development | 11/07/2024 | By Aishwarya |  975

Lupin Gets Tentative Approval from US FDA for Empagliflozin, Linagliptin and Metformin Hydrochloride

Lupin has secured tentative approval from the United States Food and Drug Administration (US FDA)for its Abbreviated New Drug Application for Empagliflozin, Linagliptin and Metformin Hydrochloride Extended-Release (ER) Tablets.

Drug Discovery & Development | 10/07/2024 | By Aishwarya |  849

Hinova Pharma Secures FDA Fast Track Designation for HP518

Hinova Pharmaceuticals Inc. has announced that the US Food and Drug Administration (FDA) has granted Fast Track designation for HP518, an investigational drug for the treatment of Androgen-receptor positive (AR+) triple-negative breast cancer (TNBC).

Drug Discovery & Development | 08/07/2024 | By Aishwarya |  774

Alembic Pharma Gets Tentative Approval from FDA for Ivosidenib Tablets

Alembic Pharmaceuticals has received tentative approval from the US Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Ivosidenib Tablets, 250 mg.

Drug Discovery & Development | 05/07/2024 | By Aishwarya |  613

Aurigene and Edity to Partner in Cell Therapy

Aurigene Pharmaceutical Services Ltd. has announced that it will provide discovery services to Edity Therapeutics in cell therapy.

Drug Discovery & Development | 03/07/2024 | By Aishwarya |  726

EMA Accepts Approval for AstraZeneca MAA for Sipavibart

AstraZeneca has announced that its Marketing Authorisation Application (MAA) for sipavibart has been accepted under an accelerated assessment procedure by the European Medicines Agency (EMA), for the pre-exposure prophylaxis (prevention) of COVID-19 in immunocompromised patients.

Drug Discovery & Development | 02/07/2024 | By Aishwarya |  690